Sofie Biosciences

Warning letter

Headquarters

United States of America

Issue date

10 Oct 2019

Issuing office

Division of Pharmaceutical Quality Operations II

Posted date

22 Oct 2019

Subject

CGMP/Positron Emission Tomography (PET) Drugs/Adulterated

Products & Services

Drugs